The FDA Just Told Smokers a Nicotine Pouch Is Safer. Nobody Told the 13-Year-Old Buying the Same Can.

On July 2, the FDA authorized 20 ZYN products — 10 flavors, two nicotine strengths — to carry a claim on the label that using them puts you at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis than smoking cigarettes. It’s the first modified-risk order the agency has ever granted a nicotine pouch. On the science of relative harm, the claim is probably defensible — a pouch you tuck under your lip is not a burning cigarette, and there’s real public-health value in giving the country’s remaining 24 million adult smokers a lower-harm way to get their nicotine.

A label written for a 45-year-old two-pack-a-day smoker doesn’t stay in that lane once it’s on a shelf a teenager can reach.

That’s the part the FDA’s order can’t control and the part that should worry you more than the claim itself. Nicotine pouch sales nearly tripled from $145 million to $404 million between January 2023 and December 2024, and the FDA’s own 2025 Youth Tobacco Survey found that among the middle and high schoolers who use pouches, more than one in six use them daily and more than nine in ten use flavored versions — cinnamon, citrus, mint, the same flavor logic that built the vaping crisis this exact agency spent a decade fighting. A “lower risk than cigarettes” label doesn’t distinguish between the smoker it’s meant for and the kid who’s never smoked a cigarette in his life and is starting his nicotine dependence at 13 instead.

This isn’t a hypothetical trade-off. It’s the same one the country just ran, in real time, with vaping — and the smoking numbers actually back up the case for harm reduction done right: adult cigarette smoking hit a historic low of 9.1% in 2025, down from a 1965 peak of 42.4%, and lower-harm nicotine products for adult smokers who can’t or won’t quit outright are part of why. The tension isn’t harm reduction versus abstinence. It’s whether a regulator can write a claim precise enough to reach the smoker it’s for without also reaching the kid it isn’t.

The FDA’s order doesn’t include an age-verification mandate on point-of-sale marketing, a flavor restriction, or a cap on where “modified risk” packaging can appear. If the agency wants credit for shrinking smoking, it needs the other half of that job too — the half that keeps this claim off a can a 13-year-old can buy at a gas station on the way to school.